Ledger · 2026-08-28 · Medical Nanomaterials

High-Yield Biomanufactured Magnetosomes (FIONs) for Ultra-High Relaxivity MRI

Rejected

This concept did not clear the framework. The reasoning is published in full below.

Why it failed

• Voided by: Illegitimate incumbent, Capital and time to revenue

Assessment

This venture fails sub-test A by anchoring performance and margins to Feridex, a discontinued/withdrawn contrast agent. It also fails sub-test C because human clinical MRI contrast agents require extensive IND approvals and clinical trials, exceeding $5M in pre-revenue CapEx and taking several years before first revenue.

Claimed advantage

r2 relaxivity of 324-471 mM-1 s-1 vs 133 mM-1 s-1 for Feridex

Named comparator: Feridex / Resovist / Gadolinium Chelates

Also flagged

• Comparator may have left the market
• Evidence rests on non-peer-reviewed sources
• Duplicate references inflating the evidence base

A rejection is not a claim that the science is wrong. It means the venture case did not survive: the comparator was not what the buyer actually buys, the comparison was not like-for-like, the advantage fell short of a step change, or the capital and time to first revenue were prohibitive.

---

Assessed 2026-08-28 against seven gates plus the voiding sub-tests. How the method works · Browse all concepts